AU5706486A - Pharmaceutical compositions containing pyridinone compounds - Google Patents
Pharmaceutical compositions containing pyridinone compoundsInfo
- Publication number
- AU5706486A AU5706486A AU57064/86A AU5706486A AU5706486A AU 5706486 A AU5706486 A AU 5706486A AU 57064/86 A AU57064/86 A AU 57064/86A AU 5706486 A AU5706486 A AU 5706486A AU 5706486 A AU5706486 A AU 5706486A
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- pyridinone compounds
- containing pyridinone
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3515882 | 1985-05-03 | ||
| DE19853515882 DE3515882A1 (en) | 1985-05-03 | 1985-05-03 | MEDICINAL PRODUCTS CONTAINING PYRIDINONE WITH ANTITHROMBOTIC EFFECTS AND METHOD FOR THE PRODUCTION THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5706486A true AU5706486A (en) | 1986-11-06 |
Family
ID=6269707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU57064/86A Abandoned AU5706486A (en) | 1985-05-03 | 1986-05-02 | Pharmaceutical compositions containing pyridinone compounds |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0210342A2 (en) |
| JP (1) | JPS61254524A (en) |
| AU (1) | AU5706486A (en) |
| DE (1) | DE3515882A1 (en) |
| DK (1) | DK200586A (en) |
| ZA (1) | ZA863304B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3533542B2 (en) * | 1994-03-08 | 2004-05-31 | 株式会社大塚製薬工場 | Phosphonic acid diester derivatives |
| US6642244B2 (en) | 2001-03-16 | 2003-11-04 | Bristol-Myers Squibb Co. | Pyrazolopyridopyrimidine inhibitors of cGMP phosphodiesterase |
| EP2332527A3 (en) | 2004-10-20 | 2011-11-16 | Resverlogix Corp. | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases |
| PL2118074T3 (en) * | 2007-02-01 | 2014-06-30 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
| CN101531638B (en) * | 2008-03-13 | 2011-12-28 | 中国科学院广州生物医药与健康研究院 | Compound used as a regulator of estrogen-related receptor and applications thereof |
| NZ586440A (en) | 2008-06-26 | 2011-07-29 | Resverlogix Corp | Methods of preparing quinazolinone derivatives |
| CN101628913B (en) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | Compound as estrogen-related receptor modulator and application thereof |
| ES2463097T3 (en) * | 2009-01-08 | 2014-05-27 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
| NZ596117A (en) | 2009-04-22 | 2014-10-31 | Resverlogix Corp | Novel anti-inflammatory agents |
| HUE044986T2 (en) | 2011-11-01 | 2019-11-28 | Resverlogix Corp | Oral immediate release formulations for substituted quinazolinones |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| KR20150096794A (en) | 2012-12-21 | 2015-08-25 | 제니쓰 에피제네틱스 코포레이션 | Novel heterocyclic compounds as bromodomain inhibitors |
| CN114984016A (en) | 2015-03-13 | 2022-09-02 | 雷斯韦洛吉克斯公司 | Compositions and methods for treating complement-associated diseases |
-
1985
- 1985-05-03 DE DE19853515882 patent/DE3515882A1/en not_active Withdrawn
-
1986
- 1986-02-28 JP JP61043874A patent/JPS61254524A/en active Pending
- 1986-04-16 EP EP86105280A patent/EP0210342A2/en not_active Withdrawn
- 1986-05-01 DK DK200586A patent/DK200586A/en not_active Application Discontinuation
- 1986-05-02 ZA ZA863304A patent/ZA863304B/en unknown
- 1986-05-02 AU AU57064/86A patent/AU5706486A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA863304B (en) | 1988-01-27 |
| DK200586A (en) | 1986-11-04 |
| DK200586D0 (en) | 1986-05-01 |
| JPS61254524A (en) | 1986-11-12 |
| DE3515882A1 (en) | 1986-11-06 |
| EP0210342A2 (en) | 1987-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB8626808D0 (en) | Pharmaceutical compositions | |
| GB2174904B (en) | Vasculoprotecting pharmaceutical compositions | |
| GB2171600B (en) | Pharmaceutical compositions | |
| AU5706486A (en) | Pharmaceutical compositions containing pyridinone compounds | |
| GB8602625D0 (en) | Pharmaceutical compositions | |
| EP0197752A3 (en) | Pharmaceutical compositions | |
| GB8618820D0 (en) | Pharmaceutical compositions | |
| GB8618249D0 (en) | Pharmaceutical compositions | |
| GB8515170D0 (en) | Pharmaceutical compositions | |
| GB8602602D0 (en) | Pharmaceutical compositions | |
| IL79980A0 (en) | Pharmaceutical composition containing ypsilon-interferon | |
| GB8607848D0 (en) | Pharmaceutical compositions | |
| GB8618590D0 (en) | Pharmaceutical compositions | |
| SG92592G (en) | Pharmaceutical compositions containing azanaphthalenes | |
| AU587505B2 (en) | Pharmaceutical compositions | |
| GB8610970D0 (en) | Pharmaceutical compositions | |
| GB8602601D0 (en) | Pharmaceutical compositions | |
| GB8523531D0 (en) | Pharmaceutical compositions | |
| GB8522327D0 (en) | Pharmaceutical compositions | |
| GB8618589D0 (en) | Pharmaceutical compositions | |
| GB8502887D0 (en) | Pharmaceutical compositions | |
| GB8608310D0 (en) | Pharmaceutical compositions | |
| GB8608309D0 (en) | Pharmaceutical compositions | |
| AU5502786A (en) | Substituted 1,8-naphthyridionones, processes for their preparation and pharmaceutical compositions containing them | |
| NZ217898A (en) | Pharmaceutical compositions containing aroylthiazolones |